T. Rowe Price Biotech ETF (TDNA US)
TDNA US$25.40
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 25.40
- Change
- ▲ 0.41 (1.63)
- Bid / Ask
- 21.04 - 37.66
- Volume
- 262
- Turnover
- 2,540
- Open
- 25.40
- Day Range
- 25.40 - 25.40
- VWAP
- 25.40
- Prev Close
- 24.99
- Last Trade
- 29/10 11:50am
Fund profile
Displays who issues the fund, how it is structured and invests, its Morningstar category and benchmark, size, headline costs and dates, sourced from Morningstar. Fund size counts every class of the fund; ETF net assets is this listing alone.
Fund size
$10.1M
OCT 2026
Distributions
Annually
Since inception
0.1 yrs
SEP 2026
- Legal name
- T. Rowe Price Biotech ETF
- Issuer
- T. Rowe Price
- Type
- Exchange-Traded Fund
- Structure
- Open Ended Investment Company
- Management style
- Actively managed
- Morningstar category
- Health
- Category index
- Morningstar US Health TR USD
- Benchmark
- N/A
- ETF net assets
- $10.1M
- Units on issue
- 425,057
- Management fee
- 0.55% p.a.
- Domicile
- United States
- Base currency
- USD
- Inception
- 16 SEP 2026
- Listed
- 17 SEP 2026
Objective and strategy
The investment seeks to provide long-term capital appreciation. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of biotechnology companies. It defines biotechnology companies as companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. The fund references the MSCI GICS (Global Industry Classification Standard) biotechnology and pharmaceuticals industries to identify such companies. The fund is non-diversified.
Asset allocation
Displays how the fund is split between shares, bonds, cash and other assets, sourced from Morningstar.
US equity 96.35%Non-US equity 2.36%
| Asset class | Net % | Long % | Short % |
|---|---|---|---|
| Equity | 98.71 | 98.71 | — |
| Bond | 0.00 | 0.00 | — |
| Cash | 0.00 | 0.00 | — |
| Other | 1.29 | 1.29 | — |
Sector exposure
Displays the share of the fund held in each sector, sourced from Morningstar.
Cyclical 0.00%Sensitive 0.00%Defensive 100.00%
- Healthcare
- 100.00%
- Basic Materials
- 0.00%
- Consumer Cyclical
- 0.00%
- Financial Services
- 0.00%
- Real Estate
- 0.00%
- Communication Services
- 0.00%
- Energy
- 0.00%
- Industrials
- 0.00%
- Technology
- 0.00%
- Consumer Defensive
- 0.00%
- Utilities
- 0.00%
Region exposure
Displays the share of the fund held in each region, sourced from Morningstar.
Developed markets 100.00%Emerging markets 0.00%
- North America
- 98.26%
- United Kingdom
- 1.48%
- Europe Developed
- 0.26%
- Latin America
- 0.00%
- Europe Emerging
- 0.00%
- Africa / Middle East
- 0.00%
- Japan
- 0.00%
- Australasia
- 0.00%
- Asia Developed
- 0.00%
- Asia Emerging
- 0.00%
Country exposure
Displays the twelve countries the fund holds most of, sourced from Morningstar.
- United States
- 97.61%
- United Kingdom
- 1.48%
- Canada
- 0.65%
- France
- 0.26%
Style box
Displays where the fund's shareholdings sit on Morningstar's style box: size (large, mid, small) down and investment style (value, blend, growth) across, sourced from Morningstar.
LargeMidSmallValueBlendGrowth
- Style
- Small Growth
Size score
68
Small
Mid
Large
Value-growth score
228
Value
Blend
Growth
Economic moat
None 53%Narrow 37%Wide 10%
Market capitalisation
Displays the share of the fund's shareholdings in giant, large, mid, small and micro cap companies, sourced from Morningstar.
- Giant
- 0.00%
- Large
- 5.45%
- Mid
- 22.39%
- Small
- 49.16%
- Micro
- 23.01%
Large 5%Mid 22%Small 49%Micro 23%
- Average market cap
- $9.33B
- Number of holdings
- 88
- Shares held
- 87
Portfolio statistics · 23 OCT 2026
Displays the valuation, yield, size, concentration and quality of the fund's shareholdings taken together (trailing twelve months), sourced from Morningstar.
- Price / book
- 5.79
- Price / sales
- 12.82
- Dividend yield
- 0.05%
- Assets in top 10
- 27.92%
- Return on equity
- -22.60%
Top holdings · top 10 = 27.84% of assets
Displays the fund's ten largest holdings and their weight in the portfolio, sourced from Morningstar.
| Holding | % Weight | First bought | Market value | Currency | Units held | Sector | Country | |
|---|---|---|---|---|---|---|---|---|
| argenx SE ADR ARGX | 5.50 | SEP 2026 | 550,364 | USD | 567 | Healthcare | United States | |
| Kymera Therapeutics Inc Ordinary Shares KYMR | 4.01 | SEP 2026 | 401,041 | USD | 3,629 | Healthcare | United States | |
| Insmed Inc INSM | 2.64 | SEP 2026 | 263,752 | USD | 2,281 | Healthcare | United States | |
| Kodiak Sciences Inc KOD | 2.58 | SEP 2026 | 258,416 | USD | 2,836 | Healthcare | United States | |
| Natera Inc NTRA | 2.43 | SEP 2026 | 242,909 | USD | 586 | Healthcare | United States | |
| Revolution Medicines Inc Ordinary Shares RVMD | 2.37 | SEP 2026 | 237,401 | USD | 1,161 | Healthcare | United States | |
| Vertex Pharmaceuticals Inc VRTX | 2.28 | SEP 2026 | 228,074 | USD | 433 | Healthcare | United States | |
| Alnylam Pharmaceuticals Inc ALNY | 2.04 | SEP 2026 | 204,272 | USD | 804 | Healthcare | United States | |
| Moderna Inc MRNA | 2.02 | SEP 2026 | 201,832 | USD | 992 | Healthcare | United States | |
| United Therapeutics Corp UTHR | 1.96 | SEP 2026 | 195,958 | USD | 407 | Healthcare | United States |
Portfolio risk score
Displays Morningstar's Portfolio Risk Score for the fund's holdings, how closely the ETF tracks its index day to day, the estimated cost of holding it against the index, the cost of trading it at market size, and its best and worst quarters since inception, sourced from Morningstar.
Risk score
90.7
Cash 0
Global shares 100
Morningstar Portfolio Risk Score at 30 SEP 2026.
Fees and costs
Displays the fund's ongoing costs as a percentage of assets per year: the PDS management fees and costs, performance fee and transaction costs that make up the total cost ratio (the RG 97 forward estimate, and what was charged last financial year), and the buy / sell spread, sourced from Morningstar.
- Management fees and costs
- 0.55% p.a.
- PDS dated
- 1 AUG 2026
Fund managers
Displays the people Morningstar lists as managers of the fund, sourced from Morningstar.
- John Hall
Tenure
Displays how long the managers have run the fund: the average and longest tenure, who has served longest, the latest appointment and how many other funds the team manages, sourced from Morningstar.
- Number of managers
- 1
- Average tenure
- 0.1 years
- Longest tenure
- 0.1 years
- Longest serving
- John Hall · since 16 SEP 2026
- Most recent appointment
- John Hall · since 16 SEP 2026
- Managed since
- 16 SEP 2026
- Other funds managed
- 1
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
